Schizophrenia: Epidemiology Overview and Insights to 2024 - ResearchAndMarkets.com

DUBLIN--()--The "Schizophrenia: Epidemiology Overview and Insights" report has been added to ResearchAndMarkets.com's offering.

This report delivers an in-depth understanding of the disease and the historical & forecasted epidemiology of Schizophrenia disease in terms of diagnosed prevalent and the treated patients in the US, EU5 (Germany, France, Italy, Spain, UK), and Japan market till 2024. The epidemiology numbers in the report have been derived based on numerous studies, survey reports and views of key opinion leaders.

Disease Indication Overview: This section of the report gives the overview of Schizophrenia disease indication in detail. The section highlights the basic definition, causes and symptoms of disease and further details the types of Schizophrenia disease. Further details on the profile of Schizophrenia patients, Symptoms experienced by the patients, and disease progression in patients are outlined in the report. The report further highlights the multiple methods through which the patient can be diagnosed for Schizophrenia disease.

Epidemiology Forecasts to 2024: This section of the report provides the overview of Schizophrenia diagnosed prevalent and treated patients in the US, EU5 (Germany, France, Italy, Spain and UK) and Japan market year wise starting from 2015 till 2024. The epidemiology numbers in the report have been derived based on numerous studies, survey reports and views of key opinion leaders.

Companies Mentioned

  • Shionogi
  • Shire
  • Supernus Pharmaceuticals
  • Yale University
  • Chugai Pharmaceutical
  • Eli Lilly
  • GlaxoSmithKline
  • New River Pharmaceuticals
  • Johnson & Johnson
  • Celgene
  • Elan
  • Novartis
  • Teva Pharmaceutical Industries
  • Cephalon
  • Alkermes
  • Recro Pharma
  • Neos Therapeutics
  • Afecta Pharmaceuticals
  • Sumitomo Dainippon Pharma
  • Sepracor
  • Aquestive Therapeutics
  • KemPharm

Key Topics Covered

1. Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Executive Summary

2.1 Key Metrics

3 Disease Overview

3.1 Disease Definition

3.2 Disease Etiology and Pathophysiology

3.2.1 Etiology

3.2.2 Pathophysiology

3.2.3 Impact on Quality of Life

3.3 Symptoms of the Disease

3.4 Disease Diagnosis

3.5 Treatment Guidelines

3.6 Key Unmet Needs

4 Disease Epidemiology

4.1 Diagnosed Prevalent Patient projections by Country (Forecast till 2024)

4.2 Treated Patient projections by Country (Forecast till 2024)

For more information about this report visit https://www.researchandmarkets.com/research/5d2994/schizophrenia?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Schizophrenia Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Schizophrenia Drugs